Artemisinin-resistant Malaria in Cambodia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01736319|
Recruitment Status : Completed
First Posted : November 29, 2012
Last Update Posted : April 5, 2018
- Artemisinin-based combination therapies (ACTs) are the first-line treatments for malaria. ACTs are highly effective, but malaria caused by the Plasmodium falciparum parasite is becoming resistant to some ACTs. ACT-resistant malaria has shown up in some parts of Cambodia, but not yet in other parts of the country. This has been shown by treating patients with ACTs, checking the amount of parasites in the patient s blood every 6 hours, and calculating the rate of parasite clearance. The parasite clearance rate in response to ACTs is getting slower in western Cambodia and may be the first sign of ACT resistance. Researchers want to study how effective ACTs are in different regions of Cambodia. This study will look at the extent of ACT resistance and how widespread ACT-resistant malaria has become.
- To compare the prevalence of ACT-resistant malaria in western, northern and eastern Cambodia.
- Individuals between 2 and 65 years of age who have uncomplicated Plasmodium falciparum malaria and have not taken any antimalarial drugs for their symptoms in the previous 7 days.
- Participants will be recruited from clinics and hospitals in three Cambodian provinces.
- Participants will be informed about the study and their consent to participate in the study will be obtained.
- A venous blood sample will be obtained from patients before treatment and used for laboratory experiments to measure parasite and patient factors that might affect the parasite clearance rate.
- Participants with malaria will be treated with dihydroartemisinin-piperaquine (DHA-PPQ), the standard first-line treatment for malaria in Cambodia.
- Treatment will be monitored with frequent blood samples obtained from a finger prick. The amount of malaria parasites in each blood sample will be counted and followed until they are no longer detectable.
- Participants will have weekly follow-up visits for up to 9 weeks. Finger-prick blood samples will be taken at each visit to see if the parasites reappear after treatment with ACT.
|Condition or disease|
|Plasmodium Falciparum Malaria|
|Study Type :||Observational|
|Actual Enrollment :||561 participants|
|Official Title:||Artemisinin-resistant Plasmodium Falciparum Malaria in Cambodia|
|Study Start Date :||June 26, 2012|
|Study Completion Date :||April 6, 2016|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01736319
|National Center for Parasitology, Entomology, and Malaria Controk, Ministry of H|
|Phnom Penh, Cambodia|
|Principal Investigator:||Rick M Fairhurst, M.D.||National Institute of Allergy and Infectious Diseases (NIAID)|